Yanan Zhu
Stock Analyst at Wells Fargo
(2.19)
# 2,850
Out of 4,983 analysts
78
Total ratings
44.44%
Success rate
-3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.75 | +45.45% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $24.49 | +83.75% | 1 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $77 → $82 | $61.17 | +34.05% | 3 | Aug 22, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $16 → $12 | $1.88 | +538.30% | 4 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $7.5 → $8 | $2.90 | +175.86% | 3 | Aug 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $4 → $2.5 | $0.95 | +163.16% | 4 | Aug 13, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $6 → $5 | $1.27 | +293.70% | 4 | Aug 13, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $45 → $42 | $18.05 | +132.69% | 8 | Aug 12, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $38 | $18.00 | +111.11% | 5 | Aug 8, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $18 → $14 | $2.22 | +530.63% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $12.41 | +262.61% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $40.06 | +87.22% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $50 | $17.05 | +193.26% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.5 → $1 | $0.08 | +1,137.62% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $22.45 | +211.80% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.26 | +134.74% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $30 | $14.16 | +111.86% | 2 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $15.05 | +165.78% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $59.07 | +10.04% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.52 | +360.12% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.51 | +680.18% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.40 | +18,650.00% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $734.35 | -55.61% | 1 | Feb 2, 2021 |
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.75
Upside: +45.45%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $24.49
Upside: +83.75%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $77 → $82
Current: $61.17
Upside: +34.05%
Metagenomi
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.88
Upside: +538.30%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Overweight
Price Target: $7.5 → $8
Current: $2.90
Upside: +175.86%
Fate Therapeutics
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $0.95
Upside: +163.16%
Autolus Therapeutics
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.27
Upside: +293.70%
Arcturus Therapeutics Holdings
Aug 12, 2025
Maintains: Overweight
Price Target: $45 → $42
Current: $18.05
Upside: +132.69%
RAPT Therapeutics
Aug 8, 2025
Maintains: Overweight
Price Target: $51 → $38
Current: $18.00
Upside: +111.11%
Iovance Biotherapeutics
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.22
Upside: +530.63%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $12.41
Upside: +262.61%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $40.06
Upside: +87.22%
Aug 7, 2025
Maintains: Overweight
Price Target: $48 → $50
Current: $17.05
Upside: +193.26%
May 14, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $1
Current: $0.08
Upside: +1,137.62%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $22.45
Upside: +211.80%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.26
Upside: +134.74%
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $14.16
Upside: +111.86%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $15.05
Upside: +165.78%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $59.07
Upside: +10.04%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $6.52
Upside: +360.12%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.51
Upside: +680.18%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.40
Upside: +18,650.00%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $734.35
Upside: -55.61%